Skip to main content
Top
Published in: Clinical Rheumatology 5/2007

01-05-2007 | Case Report

Is SAPHO syndrome a target for antibiotic therapy?

Authors: A. P. Rozin, A. M. Nahir

Published in: Clinical Rheumatology | Issue 5/2007

Login to get access

Abstract

The etiology of the synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome remains unclear. Infectious factors are proposed to be relevant in the etiopathogenesis of the disease. To our knowledge, this is the first reported case of a proposed relationship between Staphylococcus aureus cultured from plantar pustule and SAPHO syndrome, which was successfully treated with co-trimoxazole (CTM) (sulfamethoxazole/trimetoprim). CTM might be the drug of choice for therapy for SAPHO syndrome because of combined antibiotic and immunomodulatory properties. Hypersensitivity testing of the medication in vitro was performed to identify, in the preclinical stage, the hypersensitivity reaction to CTM, which may have been severe.
Literature
1.
go back to reference Chamot AM, Vion B, Gerster JC (1986) Acute pseudoseptic arthritis and palmoplantar pustulosis. Clin Rheumatol 5:118–123CrossRefPubMed Chamot AM, Vion B, Gerster JC (1986) Acute pseudoseptic arthritis and palmoplantar pustulosis. Clin Rheumatol 5:118–123CrossRefPubMed
2.
go back to reference Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey, 85 cases. Rev Rhum Mal Osteoartic 54:187–196PubMed Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey, 85 cases. Rev Rhum Mal Osteoartic 54:187–196PubMed
3.
go back to reference Giedion A, Holthusen W, Masel LF, Vischer D (1972) Subacute and chronic “symmetrical” osteomyelitis. Ann Radiol (Paris) 15:329–342 Giedion A, Holthusen W, Masel LF, Vischer D (1972) Subacute and chronic “symmetrical” osteomyelitis. Ann Radiol (Paris) 15:329–342
4.
go back to reference Boutin RD, Resnick D (1998) The SAPHO syndrome: an evolving concept for unifying several idiopathic disorders of bone and skin. AJR Am J Roentgenol 170:585–591PubMed Boutin RD, Resnick D (1998) The SAPHO syndrome: an evolving concept for unifying several idiopathic disorders of bone and skin. AJR Am J Roentgenol 170:585–591PubMed
5.
go back to reference Edlund E, Johnson U, Lidgren E et al (1988) Palmoplantar pustulosis and sternoclavicular arthroosteitis. Ann Rheum Dis 47:809–815PubMedCrossRef Edlund E, Johnson U, Lidgren E et al (1988) Palmoplantar pustulosis and sternoclavicular arthroosteitis. Ann Rheum Dis 47:809–815PubMedCrossRef
6.
go back to reference Pillon P, Pajon A, Juvin R, Gaudin P, Tourne Y, Pasquier V et al (1992) Tibial hyperostopsis and propiobactgerium acnes. Rev Rhum Mal Osteoartic 59:349–351PubMed Pillon P, Pajon A, Juvin R, Gaudin P, Tourne Y, Pasquier V et al (1992) Tibial hyperostopsis and propiobactgerium acnes. Rev Rhum Mal Osteoartic 59:349–351PubMed
7.
go back to reference Wagner AD, Mai U, Hammer M, Zeidler H (1997) Long term antibiotic therapy successful in patients with SAPHO syndrome. Arthritis Rheum 40(Suppl 9):S62 Wagner AD, Mai U, Hammer M, Zeidler H (1997) Long term antibiotic therapy successful in patients with SAPHO syndrome. Arthritis Rheum 40(Suppl 9):S62
8.
go back to reference Taurog JD, Richardson JA, Croft JT et al (1994) The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364CrossRefPubMed Taurog JD, Richardson JA, Croft JT et al (1994) The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364CrossRefPubMed
9.
go back to reference Khare SD, Luthra HS, Davis CS (1995) Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies. J Exp Med 182:1153–1158CrossRefPubMed Khare SD, Luthra HS, Davis CS (1995) Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies. J Exp Med 182:1153–1158CrossRefPubMed
10.
go back to reference Klinman D (2003) Does activation of the innate immune system contribute to the development of rheumatoid arthritis? Arthritis Rheum 48:590–593CrossRefPubMed Klinman D (2003) Does activation of the innate immune system contribute to the development of rheumatoid arthritis? Arthritis Rheum 48:590–593CrossRefPubMed
11.
go back to reference Trimble BS, Evers CJ, Ballaron SA, Young JM (1987) Intraarticular injection of Propionebacterium acnes causes an erosive arthritis in rats. Agents Actions 21:281–283CrossRefPubMed Trimble BS, Evers CJ, Ballaron SA, Young JM (1987) Intraarticular injection of Propionebacterium acnes causes an erosive arthritis in rats. Agents Actions 21:281–283CrossRefPubMed
12.
go back to reference Hayem G, Bouchaud-Cabot A, Benali K, Roux S, Palazzo E (1999) SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 29:159–171CrossRefPubMed Hayem G, Bouchaud-Cabot A, Benali K, Roux S, Palazzo E (1999) SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 29:159–171CrossRefPubMed
13.
14.
go back to reference Carter J, Valeriano J, Vasey F (2004) Doxycycline versus doxycycline plus rifampycin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. J Rheumatol 31:1973–1980PubMed Carter J, Valeriano J, Vasey F (2004) Doxycycline versus doxycycline plus rifampycin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. J Rheumatol 31:1973–1980PubMed
15.
go back to reference De Remee RA, McDonald TJ, Weiland LH (1985) Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 60:27–32PubMed De Remee RA, McDonald TJ, Weiland LH (1985) Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 60:27–32PubMed
16.
go back to reference Rozin AP, Schapira D, Bergman R (2003) Alopecia areata and relapsing polychondritis or mosaic of autoimmunity? The first experience of cotrimoxazole treatment. Ann Rheum Dis 62:778–780CrossRefPubMed Rozin AP, Schapira D, Bergman R (2003) Alopecia areata and relapsing polychondritis or mosaic of autoimmunity? The first experience of cotrimoxazole treatment. Ann Rheum Dis 62:778–780CrossRefPubMed
17.
go back to reference Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004) SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology 43:658–661CrossRefPubMed Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004) SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology 43:658–661CrossRefPubMed
18.
go back to reference Whyte MP, Wenkeri D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463CrossRefPubMed Whyte MP, Wenkeri D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463CrossRefPubMed
19.
go back to reference Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z (2005) Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39:1194–1197CrossRefPubMed Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z (2005) Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39:1194–1197CrossRefPubMed
Metadata
Title
Is SAPHO syndrome a target for antibiotic therapy?
Authors
A. P. Rozin
A. M. Nahir
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0274-6

Other articles of this Issue 5/2007

Clinical Rheumatology 5/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.